Policy and Payment Factors Influencing Adoption of Low-Barrier Buprenorphine Treatment

• by Margaret Lowenstein, M. Holliday Davis, Selena Suhail-Sindhu, Gary McMurtrie, David Grande, Julia Hinckley, Shoshana V. Aronowitz

• June 16, 2026

Side Effects: Context Is the Diagnosis

This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.

• by Kerri Miller

• June 9, 2026

• 6 min

Latent class profiles of psychiatric comorbidity among substance-affected Nigerian adolescents: a population-based analysis

• by Abiodun O. Adewuya, Olushola Olibamoyo, Azizat Lebimoyo, Olabisi E. Oladipo, Arit Esangbedo

• May 20, 2026

Tracking the longitudinal course of physiologic and mental health functioning among individuals in substance use disorder treatment

• by Wendy Insalaco, Charlotte Clapham, Brett Gelino, Jami Mayo Barney, Brianna Billings, Jennifer D. Ellis, J. Gregory Hobelmann, Andrew S. Huhn, Vadim Zipunnikov, Jill A. Rabinowitz

• June 10, 2026